Related references
Note: Only part of the references are listed.Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
Paola Guglielmelli et al.
BLOOD ADVANCES (2022)
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
Vikas Gupta et al.
LEUKEMIA & LYMPHOMA (2021)
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
Damien Luque Paz et al.
BLOOD ADVANCES (2021)
Paradigm shift: combination BET and JAK inhibition in myelofibrosis
John Mascarenhas et al.
LEUKEMIA (2021)
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N. Harrison et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Francesca Palandri et al.
CANCER (2020)
Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States
Srdan Verstovsek et al.
ANNALS OF HEMATOLOGY (2020)
Management of myelofibrosis after ruxolitinib failure
Claire N. Harrison et al.
ANNALS OF HEMATOLOGY (2020)
Novel therapeutics in myeloproliferative neoplasms
Sangeetha Venugopal et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
Margherita Maffioli et al.
BLOOD ADVANCES (2019)
The role of JAK2 inhibitors in MPNs 7 years after approval
Francesco Passamonti et al.
BLOOD (2018)
How I treat myelofibrosis after failure of JAK inhibitors
Animesh Pardanani et al.
BLOOD (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
Ayalew Tefferi et al.
LEUKEMIA (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
Andrew T. Kuykendall et al.
ANNALS OF HEMATOLOGY (2018)
Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients
F. Passamonti et al.
LEUKEMIA (2017)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
F. Passamonti et al.
LEUKEMIA (2017)
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
Lucia Masarova et al.
LEUKEMIA RESEARCH (2017)
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
Francesca Palandri et al.
ONCOTARGET (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
How to define treatment failure for JAK inhibitors
Hans Michael Kvasnicka
LANCET HAEMATOLOGY (2017)
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval
Andrew T. Kuykendall et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Kate J. Newberry et al.
BLOOD (2017)
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
Giada Rotunno et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Mohamed Shanavas et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Vikas Gupta et al.
HAEMATOLOGICA (2016)
JAK2V617F allele burden ≥50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
G. Barosi et al.
LEUKEMIA (2016)
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Vikas Gupta et al.
HAEMATOLOGICA (2016)
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel et al.
BLOOD (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2015)
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
G. Barosi et al.
LEUKEMIA (2015)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi et al.
BLOOD (2014)
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
Paola Guglielmelli et al.
BLOOD (2014)
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
John T. Reilly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
A. Tefferi et al.
LEUKEMIA (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
Definition and management of ruxolitinib treatment failure in myelofibrosis
A. Pardanani et al.
BLOOD CANCER JOURNAL (2014)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Ruxolitinib Discontinuation In Patients With Myelofibrosis: A Analysis From Clinical Practice
Eileen Fonseca et al.
BLOOD (2013)
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Srdan Verstovsek et al.
BLOOD (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Share Paper
